z-logo
open-access-imgOpen Access
Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257
Author(s) -
Ighovwerha Ofotokun,
Lumine H Na,
Raphael J. Landovitz,
Heather J. Ribaudo,
Grace A. McComsey,
Catherine Godfrey,
Francesca Aweeka,
Susan E. Cohn,
Manish Sagar,
Daniel R. Kuritzkes,
Todd T. Brown,
Kristine B. Patterson,
Michael F. Para,
Randi Y. Leavitt,
Angelina Villası́s-Keever,
Bryan Baugh,
Jeffrey L. Lennox,
Judith S. Currier
Publication year - 2015
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/civ193
Subject(s) - darunavir , ritonavir , raltegravir , atazanavir , medicine , cart , pharmacology , regimen , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , virology , mechanical engineering , engineering
Metabolic effects following combination antiretroviral therapy (cART) vary by regimen type. Changes in metabolic effects were assessed following cART in the AIDS Clinical Trials Group (ACTG) A5257 study, and correlated with plasma ritonavir trough concentrations (C24).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom